KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Cash from Operations (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Cash from Operations for 8 consecutive years, with 2055000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 116.45% to 2055000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 45986000.0 through Dec 2025, up 51.7% year-over-year, with the annual reading at 45986000.0 for FY2025, 51.7% up from the prior year.
  • Cash from Operations hit 2055000.0 in Q4 2025 for Adaptive Biotechnologies, up from 7127000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 2055000.0 in Q4 2025 to a low of 64453000.0 in Q1 2022.
  • Historically, Cash from Operations has averaged 33709700.0 across 5 years, with a median of 33616000.0 in 2021.
  • Biggest five-year swings in Cash from Operations: tumbled 84.28% in 2021 and later skyrocketed 116.45% in 2025.
  • Year by year, Cash from Operations stood at 53826000.0 in 2021, then soared by 44.23% to 30019000.0 in 2022, then grew by 10.28% to 26932000.0 in 2023, then surged by 53.62% to 12491000.0 in 2024, then surged by 116.45% to 2055000.0 in 2025.
  • Business Quant data shows Cash from Operations for ADPT at 2055000.0 in Q4 2025, 7127000.0 in Q3 2025, and 12430000.0 in Q2 2025.